Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246532 | 0.93 | CYP3A4 (0.45) | MDM4TP53PTPN1 | |
| SCHEMBL2252014 | 0.89 | MDM4 (0.47) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL30524109 | 0.88 | MDM4 (0.49) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL2247204 | 0.88 | MDM4 (0.49) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL28792081 | 0.84 | HDAC1 (0.54) | MDM4TP53PTPN1 | |
| SCHEMBL23421255 | 0.84 | KMT2A (0.50) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL29682496 | 0.84 | KMT2A (0.50) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL2248534 | 0.83 | MDM4 (0.46) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL5182292 | 0.83 | MDM4 (0.56) | MDM4TP53PTPN1TLR2CASP3 | |
| SCHEMBL800090 | 0.83 | MDM4 (0.56) | MDM4TP53PTPN1TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | MDM4 4353/4885TP53 4136/4885PTPN1 4403/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | MDM4 4353/4885TP53 4136/4885PTPN1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.